pharma · Gram-negative Bacterial Infections · SARS-CoV-2 Infection
Shionogi B.V.
Shionogi Inc. (U.S.) drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Shionogi Inc. (U.S.) drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antiinfectives for systemic use (J01) compound in Shionogi Inc. (U.S.)'s portfolio. Molecular target: Bacterial penicillin-binding protein.
Development asset linked to Shionogi Inc. (U.S.) in public FDA and regional records.
Development asset linked to Shionogi Inc. (U.S.) in public FDA and regional records.
Development asset linked to Shionogi Inc. (U.S.) in public FDA and regional records.
Development asset linked to Shionogi Inc. (U.S.) in public FDA and regional records.
Development asset linked to Shionogi Inc. (U.S.) in public FDA and regional records.
Antiinfectives for systemic use (J07) compound in Shionogi Inc. (U.S.)'s portfolio. Molecular target: Fusion glycoprotein F0.
Development asset linked to Shionogi Inc. (U.S.) in public FDA and regional records.